Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes

Blood

Volumn 128, Issue 9, 2016, Pages 1226-1233

  Kortüm, K Martin ^a,b   Mai, Elias K ^c   Hanafiah, Nur H ^c   Shi, Chang Xi ^a   Zhu, Yuan Xiao ^a   Bruins, Laura ^a   Barrio, Santiago ^a   Jedlowski, Patrick ^a   Merz, Maximilian ^c   Xu, Jing ^c   Stewart, Robert A ^a   Andrulis, Mindaugas ^c   Jauch, Anna ^d   Hillengass, Jens ^c   Goldschmidt, Hartmut ^c,e   Bergsagel, P Leif ^a   Braggio, Esteban ^a   Stewart, A Keith ^a,f   Raab, Marc S ^c  

^a MAYO CLINIC   (United States)

^b University Medicine of Würzburg   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^f MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CEREBLON PROTEIN; IMMUNOMODULATING AGENT; K RAS PROTEIN; LENALIDOMIDE; N RAS PROTEIN; POMALIDOMIDE; PROTEASOME INHIBITOR; PROTEIN; PROTEIN P53; RAS PROTEIN; UNCLASSIFIED DRUG; BRAF PROTEIN, HUMAN; CRBN PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE; KRAS PROTEIN, HUMAN; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN; PEPTIDE HYDROLASE; PROTEIN P21; TP53 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CANCER RESISTANCE; CELL ISOLATION; CLINICAL ARTICLE; FEMALE; GENE MUTATION; HUMAN; IN VITRO STUDY; MALE; MONONUCLEAR CELL; MULTIPLE MYELOMA; MUTATIONAL ANALYSIS; ONCOGENE K RAS; ONCOGENE N RAS; PREVALENCE; PRIORITY JOURNAL; REFRACTORY MULTIPLE MYELOMA; SEQUENCE ANALYSIS; SITE DIRECTED MUTAGENESIS; CLINICAL TRIAL; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; HIGH THROUGHPUT SEQUENCING; MIDDLE AGED; MUTATION; SIGNAL TRANSDUCTION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DRUG RESISTANCE, NEOPLASM; FEMALE; GTP PHOSPHOHYDROLASES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MULTIPLE MYELOMA; MUTATION; PEPTIDE HYDROLASES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85014904054     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-02-698092     Document Type: Article

References (60)

1. Walker BA, Boyle EM, Wardell CP, et al. Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. J Clin Oncol. 2015;33(33):3911-3920.
2. Bolli N, Avet-Loiseau H, Wedge DC, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014;5:2997.
3. Lohr JG, Stojanov P, Carter SL, et al; Multiple Myeloma Research Consortium. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014;25(1):91-101.
4. Lonial S, Yellapantula VD, Liang W, et al. Interim Analysis of the MMRF CoMMpass Trial: Identification of Novel Rearrangements Potentially Associated with Disease Initiation and Progression [abstract]. Blood. 2014;124(21). Abstract 722.
5. Keats JJ, Speyer G, Christophe L, et al. Identification of Initiating Trunk Mutations and Distinct Molecular Subtypes: An Interim Analysis of the MMRF CoMMpass Study [abstract]. Blood. 2015;126(23). Abstract 722.
6. Hofsteop Bruinink D, Kortüm KM, van Duin M, et al. M3P Sequencing Panel Identifies TP53 Mutational Status As a Prognostic Factor in Chemotherapy-Naive Multiple Myeloma [abstract]. Blood. 2015;126(23). Abstract 2984.
7. Kortuem KM, Braggio E, Bruins L, et al. Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients. Blood Cancer J. 2016;6:e397.
8. Egan JB, Shi CX, Tembe W, et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood. 2012; 120(5):1060-1066.
9. Melchor L, Brioli A, Wardell CP, et al. Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. Leukemia. 2014;28(8):1705-1715.
10. Keats JJ, Chesi M, Egan JB, et al. Clonal competition with alternating dominance in multiple myeloma. Blood. 2012;120(5):1067-1076.
11. Kortüm KM, Zhu YX, Shi CX, Jedlowski P, Stewart AK. Cereblon binding molecules in multiple myeloma. Blood Rev. 2015;29(5):329-334.
12. Zhu YX, Braggio E, Shi CX, et al. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. Blood. 2014;124(4):536-545.
13. Schuster SR, Kortuem KM, Zhu YX, et al. The clinical significance of cereblon expression in multiple myeloma. Leuk Res. 2014;38(1):23-28.
14. Zhu YX, Braggio E, Shi CX, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood. 2011; 118(18):4771-4779.
15. Heintel D, Rocci A, Ludwig H, et al. High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. Br J Haematol. 2013;161(5):695-700.
16. Broyl A, Kuiper R, van Duin M, et al; Dutch-Belgian HOVON group; German GMMG Group. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood. 2013;121(4):624-627.
17. Krönke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014; 343(6168):301-305.
18. Lu G, Middleton RE, Sun H, et al. The myeloma drug lenalidomide promotes the cereblondependent destruction of Ikaros proteins. Science. 2014;343(6168):305-309.
19. Egan JB, Kortuem KM, Kurdoglu A, et al. Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease. Br J Haematol. 2013;161(5):748-751.
20. Donner KM, Hiltunen TP, Jänne OA, Sane T, Kontula K. Generalized glucocorticoid resistance caused by a novel two-nucleotide deletion in the hormone-binding domain of the glucocorticoid receptor gene NR3C1. Eur J Endocrinol. 2012; 168(1):K9-K18.
21. Shuqing L, Jianmin Y, Chongmei H, Hui C, Wang J. Upregulated expression of the PSMB5 gene may contribute to drug resistance in patient with multiple myeloma when treated with bortezomib-based regimen. Exp Hematol. 2011;39(12):1117-1118.
22. O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood. 2007;110(7):2242-2249.
23. Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014; 370(24):2286-2294.
24. Durie BG, Harousseau JL, Miguel JS, et al; International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-1473.
25. Endris V, Penzel R, Warth A, et al. Molecular diagnostic profiling of lung cancer specimens with a semiconductor-based massive parallel sequencing approach: feasibility, costs, and performance compared with conventional sequencing. J Mol Diagn. 2013;15(6):765-775.
26. Kocher JP, Quest DJ, Duffy P, et al. The Biological Reference Repository (BioR): a rapid and flexible system for genomics annotation. Bioinformatics. 2014;30(13):1920-1922.
27. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009;4(7):1073-1081.
28. Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protoc Hum Genet. 2013; Chapter 7:Unit7 20.
29. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7(4):248-249.
30. Choi Y, Sims GE, Murphy S, Miller JR, Chan AP. Predicting the functional effect of amino acid substitutions and indels. PLoS One. 2012;7(10): e46688.
31. Rustad EH, Dai HY, Hov H, et al. BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis. Blood Cancer J. 2015;5:e299.
32. Andrulis M, Lehners N, Capper D, et al. Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov. 2013;3(8):862-869.
33. Sen B, Peng S, Tang X, et al. Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib. Sci Transl Med. 2012;4(136):136ra70.
34. Damm F, Mylonas E, Cosson A, et al. Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov. 2014;4(9):1088-1101.
35. Shain AH, Garrido M, Botton T, et al. Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. Nat Genet. 2015;47(10):1194-1199.
36. Tartaglia M, Niemeyer CM, Fragale A, et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet. 2003;34(2):148-150.
37. Bentires-Alj M, Paez JG, David FS, et al. Activating mutations of the noonan syndromeassociated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res. 2004;64(24):8816-8820.
38. Chamberlain PP, Lopez-Girona A, Miller K, et al. Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat Struct Mol Biol. 2014;21(9):803-809.
39. Fischer ES, Böhm K, Lydeard JR, et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature. 2014;512(7512):49-53.
40. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8): 765-773.
41. Marcucci G, Maharry K, Wu YZ, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2010;28(14): 2348-2355.
42. Rohle D, Popovici-Muller J, Palaskas N, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013;340(6132):626-630.
43. Wang F, Travins J, DeLaBarre B, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science. 2013;340(6132): 622-626.
44. Liao RG, Jung J, Tchaicha J, et al. Inhibitorsensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res. 2013; 73(16):5195-5205.
45. Gust KM, McConkey DJ, Awrey S, et al. Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer. Mol Cancer Ther. 2013;12(7):1245-1254.
46. Gallo LH, Nelson KN, Meyer AN, Donoghue DJ. Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations. Cytokine Growth Factor Rev. 2015;26(4):425-449.
47. Dienstmann R, Rodon J, Prat A, et al. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Ann Oncol. 2014;25(3):552-563.
48. Scheid C, Reece D, Beksac M, et al. Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation. Eur J Haematol. 2015;95(4): 316-324.
49. Heuck CJ, Jethava Y, Khan R, et al. Inhibiting MEK in MAPK pathway-activated myeloma. Leukemia. 2016;30(4):976-980.
50. Steinbrunn T, Stühmer T, Sayehli C, Chatterjee M, Einsele H, Bargou RC. Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma. Br J Haematol. 2012;159(4):430-440.
51. Niihori T, Aoki Y, Narumi Y, et al. Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet. 2006;38(3):294-296.
52. Guan J, Gupta R, Filipp FV. Cancer systems biology of TCGA SKCM: efficient detection of genomic drivers in melanoma. Sci Rep. 2015;5:7857.
53. Stieglitz E, Taylor-Weiner AN, Chang TY, et al. The genomic landscape of juvenile myelomonocytic leukemia. Nat Genet. 2015;47(11):1326-1333.
54. Prahallad A, Heynen GJ, Germano G, et al. PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs. Cell Reports. 2015;12(12): 1978-1985.
55. Grosskopf S, Eckert C, Arkona C, et al. Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo. Chem Med Chem. 2015; 10(5):815-826.
56. Aoki Y, Niihori T, Inoue S, Matsubara Y. Recent advances in RASopathies. J Hum Genet. 2016; 61(1):33-39.
57. Schmitt MW, Loeb LA, Salk JJ. The influence of subclonal resistance mutations on targeted cancer therapy. Nat Rev Clin Oncol. 2016;13(6): 335-347.
58. Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012; 486(7404):532-536.
59. Jänne PA. Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours. Lung Cancer. 2008;60(Suppl 2):S3-S9.
60. Engelman JA, Mukohara T, Zejnullahu K, et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest. 2006;116(10):2695-2706.